ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Repurposing niclosamide to mitigate inflammaging: a review of multi-target mechanisms in cellular senescence and age-related decline.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic low-grade inflammation, or inflammaging, drives age-related multimorbidity and cellular decline, yet pharmacological interventions targeting its root causes are lacking. Niclosamide, a WHO-listed anthelmintic with a long safety record, has recently emerged as a multi-target geroprotector with potent anti-inflammatory properties, though historical poor absorption limited its systemic use.
objectivesThis review consolidates molecular and preclinical evidence supporting niclosamide's repurposing for inflammaging, focusing on its ability to simultaneously engage core pathways of cellular aging and inflammation. It also evaluates recent data from reformulated oral formulations that achieve sustained plasma concentrations (0.5-3 µmol/L) sufficient for systemic effects. KEY
findingsNiclosamide acts through six interconnected mechanisms: (1) mild reversible mitochondrial uncoupling, limiting ROS and cGAS-STING activation; (2) mTORC1 inhibition via lysosomal deacidification, with indirect IGF-1/IGF-1R modulation through AMPK activation; (3) restoration of autophagic flux and lysosomal biogenesis via TFEB nuclear translocation; (4) selective senolytic and senomorphic effects, suppressing NF-κB and STAT3 to neutralize the senescence-associated secretory phenotype (SASP) and reduce IL-6, IL-1β, and TNF-α; (5) blockade of canonical Wnt/β-catenin signaling to prevent tissue fibrosis; and (6) rebalancing of aged immune function by downregulating PD-1/PD-L1 and upregulating Vasorin to inhibit TGFβ‑mediated fibrosis. Unlike single-pathway agents, niclosamide offers a unique polypharmacological profile that mitigates sterile inflammation at its source.
conclusionsReformulated niclosamide combines multi-target anti-inflammaging activity with a decades-long safety record. Randomized, placebo‑controlled trials targeting inflammaging, frailty, and biological age biomarkers are now an immediate translational priority.
Indexed as
Identifiers
42274789What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.